UBS Group Lowers Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $27.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target dropped by analysts at UBS Group from $30.00 to $27.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price objective suggests a potential upside of 51.64% from the stock’s current price.

A number of other analysts also recently weighed in on the company. Barclays dropped their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Finally, JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $22.00.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $17.81 on Thursday. The business has a 50 day moving average of $20.00 and a 200 day moving average of $18.48. The company has a market capitalization of $20.17 billion, a price-to-earnings ratio of -12.28, a PEG ratio of 0.97 and a beta of 0.73. Teva Pharmaceutical Industries has a 1-year low of $11.62 and a 1-year high of $22.80. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 40.20% and a negative net margin of 9.91%. On average, sell-side analysts predict that Teva Pharmaceutical Industries will post 2.62 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UMB Bank n.a. grew its stake in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after acquiring an additional 2,067 shares during the last quarter. Smithfield Trust Co grew its stake in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth $50,000. Claro Advisors LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth $52,000. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth $60,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.